Automate Your Wheel Strategy on CVS
With Tiblio's Option Bot, you can configure your own wheel strategy including CVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CVS
- Rev/Share 300.5234
- Book/Share 61.1499
- PB 1.0291
- Debt/Equity 1.0557
- CurrentRatio 0.8227
- ROIC 0.0403
- MktCap 79417955600.0
- FreeCF/Share 4.7113
- PFCF 13.3678
- PE 14.9935
- Debt/Assets 0.3178
- DivYield 0.0424
- ROE 0.0698
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CVS | Leerink Partners | Market Perform | Outperform | $55 | $75 | Feb. 13, 2025 |
| Upgrade | CVS | Cantor Fitzgerald | Neutral | Overweight | -- | -- | Feb. 12, 2025 |
| Upgrade | CVS | Edward Jones | Hold | Buy | -- | -- | Jan. 30, 2025 |
| Upgrade | CVS | Deutsche Bank | Hold | Buy | -- | $66 | Dec. 3, 2024 |
| Upgrade | CVS | Barclays | Equal Weight | Overweight | $63 | $82 | Oct. 10, 2024 |
| Upgrade | CVS | TD Cowen | Hold | Buy | $59 | $85 | Oct. 4, 2024 |
News
CVS Health: Why I'm Not Buying The Post-Earnings Share Buoyancy
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
CVS Health Corporation's Q1 2025 earnings show strong growth, with revenues up 7% YoY and adjusted EPS up 72%, but caution is advised for the long-term outlook. Despite positive quarterly results, CVS downgraded its full-year 2025 revenue guidance and faces ongoing challenges in its Medicare Advantage business. CVS is addressing issues in its Health Care Benefits division by terminating unprofitable contracts and improving star ratings, but risks remain high.
Read More
CVS Health (CVS) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
CVS Health Corporation (NYSE:CVS ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial Officer Prem Shah - Group President, CVS Health Steve Nelson - President, Aetna Larry McGrath - Chief Strategy Officer, Investor Relations Conference Call Participants Justin Lake - Wolfe Research Lisa Gill - JP Morgan Stephen Baxter - Wells Fargo Elizabeth Anderson - Evercore ISI Andrew Mok - Barclays Michael Cherny - Leerink Partners Charles Rhyee - TD Cowen Ann Hynes - Mizuho Securities Operator Good morning and …
Read More
CVS Health raises full-year profit outlook as Q1 earnings top estimates
Published: May 01, 2025 by: Proactive Investors
Sentiment: Positive
CVS Health Corp (NYSE:CVS) shares rose after the pharmacy chain raised its full-year profit guidance and delivered strong financial results for the first quarter. The company now expects 2025 adjusted earnings per share (EPS) in the range of $6 to $6.20, up from its earlier guidance of $5.75 to $6.
Read More
Compared to Estimates, CVS Health (CVS) Q1 Earnings: A Look at Key Metrics
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for CVS Health (CVS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
QCOM Earnings Sell-Off, CVS Turnaround Continues, LLY Disappoints
Published: May 01, 2025 by: Schwab Network
Sentiment: Neutral
While Microsoft (MSFT) and Meta Platforms (META) shined in the Big Tech space, Diane King Hall turns to a mixed earnings picture elsewhere on Wall Street. CVS Health (CVS) posted an earnings beat, raised guidance, and announced a Wegovy deal with Novo Nordisk (NVO), all contributing to its rally.
Read More
CVS Q1 Earnings & Revenues Beat, '25 EPS View Raised, Stock Up
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
CVS Health delivers earnings and revenue beat in the first quarter of 2025.
Read More
CVS Health Stock Surges as Q1 Results Handily Top Estimates
Published: May 01, 2025 by: Investopedia
Sentiment: Positive
CVS Health (CVS) shares powered 9% higher before the bell Thursday after the pharmacy and healthcare giant's first-quarter results handily topped estimates.
Read More
CVS Health (CVS) Q1 Earnings and Revenues Beat Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health (CVS) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.31 per share a year ago.
Read More
CVS Health's stock surges toward a one-year high after an earnings triple play
Published: May 01, 2025 by: Market Watch
Sentiment: Positive
Shares of CVS Health Corp. CVS jumped 6.6% toward a one-year high in premarket trading Thursday, after the healthcare-services company and drugstore chain scored a triple-play with its earnings report, by beating and profit and revenue and raising its full-year outlook.
Read More
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
Published: May 01, 2025 by: CNBC
Sentiment: Positive
CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark and Wegovy's manufacturer, Novo Nordisk, CVS will make the drug available to its members at "a more affordable price.
Read More
CVS tops estimates, hikes guidance as insurance business shows some improvement
Published: May 01, 2025 by: CNBC
Sentiment: Positive
CVS Health reported first-quarter revenue and profit that topped estimates and hiked its guidance, as its troubled insurance business showed some improvement during the period. The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per share.
Read More
CVS Beats Wall Street Expectations, Plans to Withdraw From ACA Business
Published: May 01, 2025 by: WSJ
Sentiment: Positive
The healthcare company also struck a deal with Novo Nordisk to sell Wegovy at a reduced price for cash-paying customers through its pharmacies.
Read More
CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
First Quarter Financial Highlights Total revenues increased to $94.6 billion, up 7.0% compared to prior year GAAP diluted EPS of $1.41 and Adjusted EPS of $2.25 Generated cash flow from operations of $4.6 billion Operational Highlights CVS Health to exit the individual exchange business Aetna® introduces new solutions to ease the patient and provider experience CVS Caremark® makes formulary update to improve access to GLP-1 drugs 2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83 Raised Adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00 Raised cash flow from …
Read More
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Read More
CVS Health: Maybe The Right Investment At The Right Time
Published: April 09, 2025 by: Seeking Alpha
Sentiment: Positive
CVS Health Corporation surged 10% intraday and ended yesterday 6% higher, driven by a new CFO announcement and increased Medicare Advantage payments. Despite a challenging fiscal 2024, CVS is undervalued with strong growth potential, expecting 3.5% revenue growth and 6-11% EPS growth in 2025. CVS remains a solid investment due to its recession-resilient business model, low tariff impact, and trading below intrinsic value.
Read More
CVS Health (CVS) Surges 5.9%: Is This an Indication of Further Gains?
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health (CVS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Measuring WBA Merger, HUM "Bonds Play," CVS & UNH Options Trades
Published: April 08, 2025 by: Schwab Network
Sentiment: Positive
Spencer Hakimian believes the healthcare sector will withstand the tariff storm well compared to other industries. On specific stocks, he doesn't expect much movement from Walgreens (WBA) after its top line earnings beat, but he expects the planned merger to shake market movement.
Read More
US Health Insurance Stocks Rally After $25 Billion Federal Boost To Medicare Payments
Published: April 08, 2025 by: Forbes
Sentiment: Positive
Health insurance stocks soared Tuesday morning on the first full day of trading after the U.S. government announced a more than 5% average increase in government reimbursement rates for 2026 Medicare Advantage plans run by private insurers.
Read More
Humana and Other Health Insurance Stocks Surge on Higher-Than-Expected Medicare Payments
Published: April 08, 2025 by: Investopedia
Sentiment: Positive
Shares of health insurance operators surged Tuesday after the government said it would pay a higher rate to Medicare insurers than previously estimated.
Read More
Why CVS Health (CVS) is Poised to Beat Earnings Estimates Again
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Live Update: High-Yield Dividends Stocks React to China's Tariff Retaliation
Published: April 04, 2025 by: 24/7 Wall Street
Sentiment: Negative
The stock market remains in freefall, today on fears of a full-blown trade war having been ignited, sending the stock market officially into correction turf.
Read More
Best performing S&P 500 stocks of Q1 2025
Published: April 04, 2025 by: Finbold
Sentiment: Positive
As the first quarter of 2025 wrapped up, the initial wave of optimism that carried markets into the new year had largely faded. Stocks opened strong, fueled by momentum from the late 2024 post-election rally, but the broader market lost ground as trade war fears and economic uncertainty weighed heavily on sentiment.
Read More
CVS Health to hold first quarter 2025 earnings conference call
Published: April 03, 2025 by: PRNewsWire
Sentiment: Neutral
WOONSOCKET, R.I. , April 3, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Thursday, May 1 st, 2025, at 8:00 a.m.
Read More
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Positive
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
Read More
The 3 Best Performing S&P 500 Stocks of 2025 Q1
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
We're nearing the end of the calendar-year Q1, with many S&P 500 stocks delivering strong performances year-to-date despite recent volatility stemming from tariff talks and other economic developments.
Read More
Stocks: Best and worst performers of Q1
Published: March 31, 2025 by: Yahoo Finance
Sentiment: Neutral
On the final day of the first quarter of 2025, Madison Mills and Julie Hyman take a look at the best and worst-performing stocks and sectors of the year so far. Among the worst performers are Deckers (DECK) and Tesla (TSLA), while CVS Health (CVS) led gains.
Read More
Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
3 Stocks to Buy As Tariff Turmoil Unfolds
Published: March 27, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Tariff turmoil has continued to provide intense volatility for the stock market, with certain sector seeing outsized losses as investors price in the risk of tariffs being put in place on a number of sectors and countries which export products to the U.S.
Read More
Why the Market Dipped But CVS Health (CVS) Gained Today
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health (CVS) closed at $67.20 in the latest trading session, marking a +1.08% move from the prior day.
Read More
Compelling Weight Management Program Data Set to Boost CVS Stock
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health shares impressive findings from its Weight Management Program.
Read More
About CVS Health Corporation (CVS)
- IPO Date 1996-11-20
- Website https://www.cvshealth.com
- Industry Medical - Healthcare Plans
- CEO Mr. J. David Joyner CEBS
- Employees 219000